Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,007
Views
12
CrossRef citations to date
0
Altmetric
Review

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

Franck Pagèsa Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France;d Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, FranceView further author information
,
Julien Taiebe Department of Gastroenterology and Gastrointestinal Oncology, Georges-Pompidou European Hospital, AP-HP, Paris, France;f Sorbonne Paris Cité, University of Paris, Paris, FranceView further author information
,
Pierre Laurent-Puigg INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe Labellisée Ligue Nationale Contre le Cancer, Université Sorbonne Paris Cité, Paris, FranceView further author information
&
Jérôme Galona Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceCorrespondence[email protected]
View further author information
Article: 1812221 | Received 13 Aug 2020, Accepted 15 Aug 2020, Published online: 28 Aug 2020

Figures & data

Figure 1. Treatment decision-tree using low pathological risk (T1-3, N1) high pathological risk (T4 and/or N2) categories, and the consensus Immunoscore (IS) with pre-defined categories (high >70%, and low <70%). The 3 years DFS rates (%) (black), and proportion of patients (%) (blue) are illustrated. The predictive value of Immunoscore is calculated comparing 3 to 6 months FOLFOX treatment using Log rank statistical test.

Figure 1. Treatment decision-tree using low pathological risk (T1-3, N1) high pathological risk (T4 and/or N2) categories, and the consensus Immunoscore (IS) with pre-defined categories (high >70%, and low <70%). The 3 years DFS rates (%) (black), and proportion of patients (%) (blue) are illustrated. The predictive value of Immunoscore is calculated comparing 3 to 6 months FOLFOX treatment using Log rank statistical test.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.